Sign in
BiophysicsbioRxiv
Preprint

Molecular determinants of ligand recognition and efficacy in the TRPM3 voltage sensor-like domain

Vikram DalaliD, Vipin Ashok RangariiD, Samuel Eriksson LidbrinkiD, Kirby T. MorelandiD, Erik R. LindahliD, Rebecca J. HowardiD, Susruta MajumdariD, Wayland W.L. ChengiD

Abstract

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable ion channel implicated in chronic pain and developmental and epileptic encephalopathies. The voltage sensor-like domain (VSLD) is a major site of pharmacological modulation, but the molecular determinants of ligand recognition and efficacy remain incompletely understood. Here we combine cryo-electron microscopy, molecular dynamics simulations, mutagenesis, and medicinal chemistry to investigate the interactions of TRPM3 with the inhibitors isosakuranetin, maprotiline, and diclofenac. We show that structurally diverse ligands occupy a common VSLD cavity but engage distinct interaction networks. Functional and computational analyses identify ligand-specific residue dependencies and support a halogen bond between diclofenac and D947 that contributes to inhibitor potency. Furthermore, esterification or amidation of the diclofenac carboxylate converts inhibition into potentiation, and mutagenesis and molecular dynamics simulations support partially overlapping VSLD configurations associated with these opposing effects. Together, these findings establish the TRPM3 VSLD as an adaptable allosteric pocket in which ligand-specific interactions shape recognition, potency, and efficacy.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISBazeli '26Zhao '22Zubcevic '18Kumar '25Collingridg '26Huffer '24
81% semantic matchBiochemistry
Bahar Bazeli, Alexander V. Shkumatov, Stephan Schenck+10 more·Nature Communications·Apr 1, 2026